Conventional and genetic evidence on the association between adiposity and CKD

Conventional and genetic evidence on the association between adiposity and CKD

<p><strong>Background </strong>The size of any causal contribution of central and general adiposity to CKD risk and the underlying mechanism of mediation are unknown.</p> <p><strong>Methods</strong> Data from 281,228 UK Biobank participants were used to est...

Detaylı Bibliyografya
Asıl Yazarlar:	Zhu, P, Herrington, WG, Haynes, R, Emberson, J, Landray, MJ, Sudlow, CLM, Woodward, M, Baigent, C, Lewington, S, Staplin, N
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	American Society of Nephrology 2020

Benzer Materyaller

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
Yazar:: Zhu, P, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
Yazar:: Zhu, P, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Evidence for the prevention and treatment of stroke in dialysis patients
Yazar:: Herrington, W, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
Yazar:: Lamprea-Montealegre, J, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Impact of CKD on household income
Yazar:: Morton, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
Yazar:: Haynes, R, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
Yazar:: Haynes, R, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
Yazar:: Staplin, N, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
Yazar:: Staplin, N, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
Yazar:: Staplin, N, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Smoking and adverse outcomes in patients With CKD: the Study of Heart and Renal Protection (SHARP)
Yazar:: Emberson, J, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
Yazar:: Herrington, W, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
Yazar:: Herrington, WG, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Bioimpedance in CKD: an untapped resource?
Yazar:: Mayne, KJ, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
Yazar:: Haynes, R, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Yazar:: Herrington, W, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Impact of primary kidney disease on the effects of empagliflozin in patients with CKD
Yazar:: Judge, PK, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Serum free light chains and the risk of ESRD and death in CKD.
Yazar:: Haynes, R, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Serum free light chains and the risk of ESRD and death in CKD
Yazar:: Haynes, R, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality
Yazar:: Zhu, D, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes
Yazar:: Mayne, KJ, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
Yazar:: Storey, B, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
Yazar:: Staplin, N, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Allocated but not treated: the silent 16% – Authors' reply
Yazar:: Horby, P, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Impact of CKD on Household Income
Yazar:: Rachael L. Morton, ve diğerleri
Baskı/Yayın Bilgisi: (2018-05-01)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Yazar:: Storey, B, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD
Yazar:: Fletcher, RA, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
Yazar:: Mayne, KM, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Yazar:: Mayne, K, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Use of gel-based separator tubes to stabilise phosphate in mailed blood samples.
Yazar:: Herrington, W, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

In CKD, the kidney failure risk equation predicted 2-y risk for ESKD better than eGFR alone
Yazar:: Aguilar-Ramirez, D, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Accelerometer-measured physical activity and functional behaviours among people on dialysis
Yazar:: Nawab, KA, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Haemodialysis, blood pressure and risk: At the limit of non-randomized evidence
Yazar:: Ng, SYA, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adults
Yazar:: Aguilar-Ramirez, D, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
Yazar:: Herrington, W, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
Yazar:: Mayne, K, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
Yazar:: Mihaylova, B, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
Yazar:: Herrington, W, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Kidney disease trials for the 21st century: innovations in design and conduct
Yazar:: Herrington, W, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
Yazar:: Emberson, JR, ve diğerleri
Baskı/Yayın Bilgisi: (2010)